Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026 11 AM EDT

Core Insights - Phio Pharmaceuticals Corp. is a clinical-stage siRNA biopharmaceutical company focused on developing therapeutics using its proprietary INTASYL® gene silencing technology to combat cancer [1][7] - The company will present at the Life Sciences Investor Forum on March 12, 2026, where CEO Robert Bitterman will discuss the INTASYL siRNA platform and recent clinical advancements [1][2] Company Highlights - Phio's lead clinical candidate, PH-762, is being evaluated as an intratumoral therapy for cutaneous squamous cell carcinoma (cSCC), melanoma, and Merkel cell carcinoma [5][7] - In a Phase 1b trial, 22 patients completed treatment across five dose-escalation cohorts, reporting a pathological response rate of approximately 65% in cSCC, with an 85% response rate in the highest-dose cohort [5] - The company plans to engage with the FDA regarding the next stage of clinical development in Q2 2026 and has sufficient cash reserves to sustain operations into the first half of 2027 [6] Event Details - The Life Sciences Investor Forum will be held on March 12, 2026, at 11:00 AM ET, allowing real-time Q&A with management [3] - Investors are encouraged to pre-register and check the online system to facilitate participation [4]